Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
C9475 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Apr 1, 2016 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
C9477 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jul 1, 2016 Dec 31, 2016 No Longer Used
C9480 Trabectedin Yondelis 0.1 mg Chemotherapy Alkylating Agent Natural Product No 2015 Jul 1, 2016 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct 1, 2016 In Use
J9034 Bendamustine Bendeka 1 mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2008 Jan 1, 2017 In Use
J8670 Rolapitant Varubi 1 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2015 Jan 1, 2017 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
J9352 Trabectedin Yondelis 0.1mg Chemotherapy Alkylating Agent Natural Product No 2015 Jan 1, 2017 In Use
J9325 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Jan 1, 2017 In Use
J9415 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan 1, 2017 In Use
J9176 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jan 1, 2017 In Use
J9285 Olaratumab Lartruvo 10 mg Immunotherapy Monoclonal Antibody PDGFR No 2016 Apr 1, 2017 In Use
C9492 Durvalumab Imfinzi 10 mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Oct 1, 2017 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
J1627 Granisetron Hydrochloride Extended Release Granisol [DSC], Sancuso, Sustol, Kytril 0.1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2016 Jan 1, 2018 In Use
J1729 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 10 mg Hormonal Therapy Progestin No 2011 Jan 1, 2018 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
J1726 Hydroxyprogesterone Caproate Makena 10 mg Hormonal Therapy Progestin No 2011 Jan 1, 2018 In Use
J9023 Avelumab Bavencio 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2018 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.